Dr. Maheswari Rajasekaran

Dr. Maheswari Rajasekaran

B.Pharm., M.Tech Industrial Biotechnology, Ph.D. Interdisciplinary Biomedical Sciences

Maheswari started her science career with an undergraduate degree in Pharmacy and later went on to complete a master’s degree in Biotechnology in India. She then pursued a Ph.D. at the University of Arkansas for Medical Sciences in the USA. Her dissertation was in the area of pharmacology and was about characterizing allosteric modulators of cannabinoid type -2 receptors as novel therapeutics for inflammatory diseases. She has published her work during her Ph.D. in peer-reviewed journals. Soon after her Ph.D., she worked as an Assistant Professor at Stella Maris College in Chennai, India. Subsequently, she started doing several science writing assignments as a freelancer. Communicating science eloquently for all types of audiences to understand is one of her strengths. She currently holds a position as a senior analyst in a private company and continues to actively pursue her passion for science writing.

Articles from Maheswari

Impact of acute kidney injury associated gene expression in human kidney cells

Impact of acute kidney injury associated gene expression in human kidney cells

SARS-CoV-2 infection leads to distinct changes in proteomic and peptidomic profiles and posttranslational modifications

SARS-CoV-2 infection leads to distinct changes in proteomic and peptidomic profiles and posttranslational modifications

COVID-19 in association with pre-existing mental and physical health issues

COVID-19 in association with pre-existing mental and physical health issues

Sarcopenia and COVID-19

Sarcopenia and COVID-19

Disparities in maternal mental health during COVID-19

Disparities in maternal mental health during COVID-19

SARS-CoV-2 S2 immunization as a pan-coronavirus vaccine approach

SARS-CoV-2 S2 immunization as a pan-coronavirus vaccine approach

Severe COVID-19 may result in premature aging in recovered patients

Severe COVID-19 may result in premature aging in recovered patients

Study suggests making COVID vaccines based on Mu variant

Study suggests making COVID vaccines based on Mu variant

Antigenic cocktail produced in Nicotiana benthamian plant as a potential COVID-19 vaccine candidate

Antigenic cocktail produced in Nicotiana benthamian plant as a potential COVID-19 vaccine candidate

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.